(Q37864081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

0 references

Chlamydia pneumoniae

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Bouwman JJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Bevers LM

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

van der Vlist WE

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Bouter KP

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Diepersloot RJ

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Investigation

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

573-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis.

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

The role of inflammation and infection in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Human cytomegalovirus seropositivity is associated with impaired vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

The L-arginine-nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

In vivo uptake of azithromycin in human coronary plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Evidence for infectious agents in cardiovascular disease and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Infections and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Infectious and inflammatory stimuli decrease endothelial nitric oxide synthase activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Enhanced cytomegalovirus infection in atherosclerotic human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Predisposition to atherosclerosis by infections: role of endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Infection and atherosclerosis: emerging mechanistic paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Absence of association between infectious agents and endothelial function in healthy young men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Procoagulant and inflammatory response of virus-infected monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Oxidative stress and endothelial nitric oxide bioactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Revisiting the kinetics of nitric oxide (NO) binding to soluble guanylate cyclase: the simple NO-binding model is incorrect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Antibiotic treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Antibiotic treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Treatment with azithromycin improves endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

Infection, Inflammation, and Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01541.X

10.1111/J.1365-2362.2005.01541.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16128864%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference